Evofem Biosciences Files 8-K on Material Agreement
Ticker: EVFM · Form: 8-K · Filed: Aug 26, 2025 · CIK: 1618835
Sentiment: neutral
Topics: material-agreement, corporate-action, filing
Related Tickers: EVFM
TL;DR
EVFM filed an 8-K on 8/26 for a material agreement dated 8/22 - big changes coming.
AI Summary
Evofem Biosciences, Inc. filed an 8-K on August 26, 2025, reporting a material definitive agreement entered into on August 22, 2025. The filing also covers modifications to security holder rights and amendments to its articles of incorporation or bylaws, along with financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions and agreements by Evofem Biosciences, which could impact its business operations, financial standing, and shareholder value.
Risk Assessment
Risk Level: medium — Material definitive agreements and changes to corporate structure can introduce significant business and financial risks.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- August 22, 2025 (date) — Date of earliest event reported
- August 26, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 001-36754 (identifier) — Commission File Number
FAQ
What is the nature of the material definitive agreement entered into by Evofem Biosciences?
The filing does not specify the details of the material definitive agreement, only that one was entered into on August 22, 2025.
What other items are covered in this 8-K filing?
The filing also covers material modifications to rights of security holders, amendments to articles of incorporation or bylaws, and financial statements and exhibits.
When was this 8-K form filed with the SEC?
The 8-K form was filed on August 26, 2025.
What is Evofem Biosciences' state of incorporation?
Evofem Biosciences, Inc. is incorporated in Delaware.
What is the Commission File Number for Evofem Biosciences?
The Commission File Number for Evofem Biosciences, Inc. is 001-36754.
Filing Stats: 2,099 words · 8 min read · ~7 pages · Grade level 15 · Accepted 2025-08-26 16:13:01
Key Financial Figures
- $1,573,000 — aggregate original principal amount of $1,573,000 (the " Notes ) into an aggregate 1,573
- $1,000 — 1 Preferred Stock has a stated value of $1,000 per share, and is convertible into shar
- $0.0154 — shares by (ii) the conversion price of $0.0154 per share, subject to adjustment as pro
- $100,000 — y for the payment of money in excess of $100,000. "Alternate Conversion Price" means the
Filing Documents
- form8-k.htm (8-K) — 61KB
- ex2-1.htm (EX-2.1) — 97KB
- ex3-1.htm (EX-3.1) — 314KB
- ex10-1.htm (EX-10.1) — 66KB
- ex3-1_001.jpg (GRAPHIC) — 39KB
- 0001641172-25-025530.txt ( ) — 852KB
- evfm-20250822.xsd (EX-101.SCH) — 3KB
- evfm-20250822_lab.xml (EX-101.LAB) — 33KB
- evfm-20250822_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: August 26, 2025 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer